. 2022 Dec 9;12(6):6980–6993. doi: 10.1002/cam4.5495

TABLE 3.

Multivariate analysis of progression‐free survival

	Univariate analysis			Multivariate analysis
				Model 1			Model 2
	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
Age (years)
<75 (n = 233)	1	0.837–1.421	0.522	1	0.850–1.469	0.427	1	0.843–1.454	0.466
≥75 (n = 188)	1.090	0.837–1.421	0.522	1.117	0.850–1.469	0.427	1.107	0.843–1.454	0.466
Sex
Female (n = 81)	1	0.898–1.796	0.176	1	0.923–1.895	0.128	1	0.954–1.949	0.089
Male (n = 340)	1.270	0.898–1.796	0.176	1.323	0.923–1.895	0.128	1.363	0.954–1.949	0.089
Etiology
Viral (n = 213)	1	0.834–1.411	0.543	1	0.771–1.330	0.928	1	0.743–1.288	0.873
Non‐viral (n = 208)	1.085	0.834–1.411	0.543	1.013	0.771–1.330	0.928	0.978	0.743–1.288	0.873
α‐fetoprotein level (ng/mL)
<100 (n = 247)	1	1.359–2.302	<0.001	1	1.264–2.227	<0.001	1	1.300–2.282	<0.001
≥100 (n = 174)	1.769	1.359–2.302	<0.001	1.678	1.264–2.227	<0.001	1.723	1.300–2.282	<0.001
BCLC stage
≤B (n = 175)	1	0.944–1.619		1	0.702–1.251	0.659	1	0.715–1.277	0.758
≥C (n = 246)	1.236	0.944–1.619		0.937	0.702–1.251	0.659	0.955	0.715–1.277	0.758
Atez/Bev therapy type
First line (n = 259)	1	0.953–1.617	0.109	1	0.842–1.451	0.472	1	0.836–1.444	0.500
Other (n = 162)	1.241	0.953–1.617	0.109	1.105	0.842–1.451	0.472	1.098	0.836–1.444	0.500
NLR
<3 (n = 247)	1	1.181–2.016	0.001	1	1.005–1.778	0.046	1	1.034–1.831	0.028
≥3 (n = 163)	1.543	1.181–2.016	0.001	1.337	1.005–1.778	0.046	1.376	1.034–1.831	0.028
GPS
0 (n = 239)	1			1
1 (n = 130)	1.495	1.118–1.999	0.007	1.361	1.008–1.837	0.044
2 (n = 52)	2.216	1.499–3.276	<0.001	1.777	1.172–2.694	0.007
Neo‐GPS
0 (n = 132)	1						1
1 (n = 212)	1.342	0.983–1.832	0.064				1.292	0.938–1.778	0.116
2 (n = 77)	2.091	1.435–3.046	<0.001				1.763	1.180–2.616	0.005

Abbreviations: Atez/Bev, atezolizumab plus bevacizumab; BCLC, Barcelona Clinic Liver Cancer; GPS, Glasgow prognostic score; NLR, neutrophil‐to‐lymphocyte ratio.